March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy and Ozempic drugs through the telehealth firm's platform, signaling an end to the dispute between the two companies.

The crucial question is whether the terms of the partnership allow for profitable expansion or merely position HIMS as a low-margin distributor.

But Hims & Hers shares are unlikely to sustain these gains over time. The stock is still down some 38% versus its year-to-date high. Hims & Hers Health Inc (NYSE: HIMS) soared nearly 50% this morning after announcing a landmark settlement and partnership with the Danish pharma giant – Novo Nordisk (NYSE: NVO).

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly

The global communications leader, who previously held roles at Eli Lilly and Kaiser Permanente, joins the world’s leading consumer health platform in its next phase of growth. The global communications leader, who previously held roles at Eli Lilly and ...

Hims & Hers is downgraded to hold as the 40% rally after Novo Nordisk’s dismissal of its lawsuit is likely driven by a short squeeze. Read my HIMS stock update.

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug